Get started
Author

María Isabel Mata‐Vázquez

Observed names: M. Isabel Mata-Vázquez, M. Isabel Mata‐Vazquez, M. Isabel Mata‐Vázquez, María Isabel Mata-Vázquez, María Isabel Mata‑Vazquez, María-Isabel Mata-Vázquez, María‐Isabel Mata‐Vázquez
ORCID: 0000-0002-3975-5211
Observed ORCID: 0000-0002-3975-5211
OpenAlex ID: A5113895307
Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia
2017 · Juan‐Carlos Hernández‐Boluda, Juan‐Gonzalo Correa, et al. · British Journal of Haematology · 46
PDF
Predictive factors for anemia response to erythropoiesis‐stimulating agents in myelofibrosis
2016 · Juan‐Carlos Hernández‐Boluda, Juan‐Gonzalo Correa, et al. · European Journal Of Haematology · 43
Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
2022 · Adrián Mosquera-Orgueira, Manuel Pérez-Encinas, et al. · HemaSphere · 31
Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
2022 · Alberto Alvarez‐Larrán, Marta Garrote, et al. · Cancer · 31
PDF
Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis
2020 · on behalf of GEMFIN and REHEVASC groups, Alberto Alvarez-Larrán, et al. · Annals of Hematology · 26
Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia
2023 · Alberto Alvarez-Larrán, Beatriz Cuevas, et al. · HemaSphere · 25
Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis
2022 · Juan‐Carlos Hernández‐Boluda, Irene Pastor‐Galán, et al. · British Journal of Haematology · 16
Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera
2022 · Ana Triguero, Alexandra Pedraza, et al. · Annals of Hematology · 15
Cytoreductive treatment in patients with CALR ‐mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia
2020 · Alberto Alvarez‐Larrán, Anna Angona, et al. · British Journal of Haematology · 15
Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis
2020 · Irene Pastor-Galán, Juan Carlos Hernández-Boluda, et al. · Medicina Clínica (English Edition) · 11
The prognostic impact of non‐driver gene mutations and variant allele frequency in primary myelofibrosis
2024 · Alberto Hernández‐Sánchez, Ángela Villaverde‐Ramiro, et al. · American Journal of Hematology · 10
PDF
Prognostic risk models for transplant decision-making in myelofibrosis
2018 · Juan-Carlos Hernández-Boluda, Arturo Pereira, et al. · Annals of Hematology · 10
Integrating AIPSS‐MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis
2024 · Adrián Mosquera‐Orgueira, Eduardo Arellano‐Rodrigo, et al. · HemaSphere · 9
PDF
Características clínico-biológicas de los pacientes con mielofibrosis: un análisis de 1.000 casos del Registro Español de Mielofibrosis
2020 · Irene Pastor-Galán, Juan Carlos Hernández-Boluda, et al. · Medicina Clínica · 9
Coexisting Myeloproliferative and Lymphoid Neoplasms: A European Multicenter Retrospective Study
2025 · Dolly Viviana Fiallo‐Suárez, Ruth Stuckey, et al. · American Journal of Hematology · 4
PDF
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis
2024 · Irene Pastor-Galán, Arturo Pereira, et al. · Leukemia · 1
Correction to: Low‑risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera
2022 · Ana Triguero, Alexandra Pedraza, et al. · Annals of Hematology · 1
PB3570 Prognostic significance of arterial or venous thrombosis on disease progression, cancer and mortality in myeloproliferative neoplasms
2026 · Eduardo Arellano-Rodrigo, Anna Angona, et al. · Research and Practice in Thrombosis and Haemostasis
PDF
Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era
2026 · Juan‐Carlos Hernández‐Boluda, Eduardo Arellano‐Rodrigo, et al. · British Journal of Haematology
Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia
2026 · Gonzalo Carreño-Tarragona, Rodrigo Gil-Manso, et al. · Leukemia
PDF
Works count: 20
Citation count: 303
H-index: 10
I10-index: 12
Year
Topic
Type